Eli Lilly & Co
LLY · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Eli Lilly & Co at a glance
In FY2025, Eli Lilly & Co reported revenue of USD 65,179 mn, EBITDA of USD 31,693 mn, EBITDA margin of 48.6%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 45,043 | 65,179 | |||
| EBITDA | 18,807 | 31,693 | |||
| EBITDA margin | 41.8% | 48.6% | |||
| Free cash flow | 3,760 | 8,972 | |||
| ROIC | 36.6% | 44.8% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas